Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.35
- Piotroski Score 5.00
- Grade Overweight
- Symbol (RDY)
- Company Dr. Reddy's Laboratories Limited
- Price $13.97
- Changes Percentage (-2.31%)
- Change -$0.33
- Day Low $13.93
- Day High $14.25
- Year High $16.89
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Last Earnings 05/09/2024
- Ex-Dividend for 5/16 Dividend 07/30/2024
- Dividend Payable 08/12/2024
- Today N/A
- Next Earnings (Estimated) 01/28/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.00
- Trailing P/E Ratio 17.84
- Forward P/E Ratio 17.84
- P/E Growth 17.84
- Net Income $55.68 B
Income Statement
Quarterly
Annual
Latest News of RDY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
RDY Stock Price | Dr. Reddy's Laboratories Ltd. ADR Stock Quote (U.S.: NYSE) | MarketWatch
Dr. Reddy's Laboratories Ltd. is a pharmaceutical company specializing in manufacturing and marketing prescription and over-the-counter products. It operates in Global Generics, Pharmaceutical Service...
By MarketWatch | 3 days ago -
Celtics head coach Joe Mazzulla featured as a clue on Jeopardy! over his love of "The Town"
Boston Celtics head coach Joe Mazzulla, known for his love of the movie "The Town," was featured as a clue on Jeopardy! in the category "Heist Films." This recognition in pop culture adds to his succe...
By CBS News | 1 week ago -
Purdy's big 4th quarter helps the 49ers overcome their mistakes and beat the Bucs
Despite numerous mistakes, the San Francisco 49ers managed a comeback win against the Tampa Bay Buccaneers, led by quarterback Brock Purdy's clutch plays in the fourth quarter. The team overcame error...
By AP NEWS | 1 week ago
